About: QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS‐CoV‐2 lower respiratory tract infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS‐CoV‐2 lower respiratory tract infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS‐CoV‐2 lower respiratory tract infection
Creator	Courjon, Johan Esnault, Vincent Dellamonica, Jean Baudouy, Delphine Bun, Sok-Sithikun Bun, Sok-Siya Marquette, Charles-Hugo Doyen, Denis Ferrari, Emile Labbaoui, Mohamed Levraut, Jacques Sartre, Benjamin Scarlatti, Didier Squara, Fabien Taghji, Philippe Theodore, Guillaume
source	Medline; PMC
abstract	Association between Hydroxychloroquine (HCQ) and Azithromycin (AZT) is under evaluation for patients with lower respiratory tract infection (LRTI) caused by the Severe Acute Respiratory Syndrome (SARS‐CoV‐2). Both drugs have a known torsadogenic potential, but sparse data are available concerning QT prolongation induced by this association. Our objective was to assess for COVID‐19 LRTI variations of QT interval under HCQ/AZT in patients hospitalized, and to compare manual versus automated QT measurements. Before therapy initiation, a baseline 12 lead‐ECG was electronically sent to our cardiology department for automated and manual QT analysis (Bazett and Fridericia’s correction), repeated 2 days after initiation. According to our institutional protocol (Pasteur University Hospital), HCQ/AZT was initiated only if baseline QTc ≤ 480ms and potassium level > 4.0 mmol/L. From March 24(th) to April 20(th) 2020, 73 patients were included (mean age 62 ± 14 y, male 67 %). Two patients out of 73 (2.7 %) were not eligible for drug initiation (QTc ≥ 500ms). Baseline average automated QTc was 415 ± 29 ms and lengthened to 438 ± 40 ms after 48 hours of combined therapy. The treatment had to be stopped because of significant QTc prolongation in 2 out of 71 patients (2.8 %). No drug‐induced life‐threatening arrhythmia, nor death was observed. Automated QTc measurements revealed accurate in comparison with manual QTc measurements. In this specific population of inpatients with COVID‐19 LRTI, HCQ/AZT could not be initiated or had to be interrupted in less than 6% of the cases.
has issue date	2020-06-26(xsd:dateTime)
bibo:doi	10.1002/cpt.1968
bibo:pmid	32588427
has license	no-cc
sha1sum (hex)	2f089827c74590d1dd30b23c35b88b99e1d2d2be
schema:url	https://doi.org/10.1002/cpt.1968
resource representing a document's title	QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS‐CoV‐2 lower respiratory tract infection
has PubMed Central identifier	PMC7361407
has PubMed identifier	32588427
schema:publication	Clin Pharmacol Ther
resource representing a document's body	covid:2f089827c74590d1dd30b23c35b88b99e1d2d2be#body_text
is schema:about of	named entity 'patients' named entity 'University Hospital' named entity 'lengthened' named entity 'cardiology' named entity 'patients' named entity 'manual' named entity 'mmol/L' named entity 'SARS-CoV-2' named entity 'LRTI' named entity 'MALE' named entity 'DATA' named entity 'VARIATIONS' named entity 'ARRHYTHMIA' named entity 'AUTOMATED' named entity 'HCQ' named entity 'manual' named entity 'measurements' named entity 'drug' named entity 'drugs' named entity 'specific' named entity 'Before' named entity 'AZT' named entity 'QTc' named entity 'QTc' named entity 'patients' named entity 'measurements' named entity 'institutional' named entity 'Two' named entity 'prolongation' named entity 'potassium' named entity 'HCQ' named entity 'QTc' named entity 'LRTI' named entity 'QTc prolongation' named entity 'QTc' named entity 'HCQ' named entity 'LRTI' named entity 'COVID' named entity 'QT interval prolongation' named entity 'SARS-CoV-2' named entity 'measurements' named entity 'research teams' named entity 'mmol/L' named entity 'COVID-19 disease' named entity 'ECG monitoring' named entity 'New York' named entity 'COVID-19 disease' named entity 'SARS-CoV-2' named entity 'manual measurement' named entity 'ECG' named entity 'beats per minute' named entity 'arrhythmogenic' named entity 'COVID' named entity 'corrected QT' named entity 'safety profile' named entity 'heart rate' named entity 'HCQ' named entity 'alimemazine' named entity 'QTc prolongation' named entity 'AZT' named entity 'HCQ' named entity 'polypharmacy' named entity 'Azithromycin' named entity 'Lower Respiratory Tract Infection' named entity 'QT prolongation' named entity 'LRTI'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software